Learn More

Browse our comprehensive and convenient portfolio of over 2,000 ELISA products, ranging from ready-to- use coated and uncoated ELISA kits—optimized for convenient and sensitive quantitation of a wide range of targets—to quality reagents and buffers for building your own plate-based immunoassays, as...

In the rapidly growing field of immuno-oncology an individual’s immune system is being employed as a new treatment modality to combat cancer. Success in discovery and development of immuno-oncology therapies relies on a knowledge of the underlying cellular mechanisms of the immune system and the...

Comprehensive solutions for cancer genomic biomarker discovery and verification across key immuno-oncology research areas Immuno-oncology research, aimed at discovering new cancer biomarkers that can become novel therapeutic targets, has experienced significant breakthroughs in cancer research...

Invitrogen ProcartaPlex immunoassays are antibody-based, magnetic bead reagent kits and panels for multiplex protein quantitation using the Luminex instrument platform. The assays cover more than 600 cytokines, chemokines, growth factors, and other protein targets from human, mouse, rat, non-human...

by S. Oehler, R. Seba, M. Miholits, and I. Rech-Weichselbraun – 04/2017, The ProcartaPlex Immuno-Oncology Checkpoint Panel is the first commercially available multiplex immunoassay system that allows simultaneous detection of the soluble forms of the following analytes: BTLA, GITR, HVEM, IDO, LAG-3,...

Targeting immune checkpoint protein interactions is one form of cancer immunotherapy that offers a novel way to attack tumor cells. The discovery of those druggable protein targets relies on an in-depth understanding of cell signaling pathways.

Reliable solutions for every stage of therapeutic antibody development, In your efforts to discover, synthesize, characterize, and optimize antibody candidates, you need reliability. When you’re ready to scale up your manufacturing, you need consistency.

The discovery and development of effective cancer immunotherapy requires a better understanding of the tumor and its surrounding environment. Different stages of cancer progression depend on the tumor, the organ in which it resides, and the immune response.

Recent advances in immuno-oncology (I-O) research are paving the way for the discovery of novel classes of cancer therapeutics that enhance or enable antitumor immune responses, overcome tumor evasion mechanisms, and promote conditions that favor immune protection.

Comprehensive solutions to support CAR T-cell therapy research from T-cell engineering to sequencing Adoptive cell transfer is a rapidly emerging area of immuno-oncology research. This approach involves collecting, manipulating, activating, and transferring a subject’s immune cells to treat cancer.

A main focus of immuno-oncology research is investigating immune checkpoint pathway functionality in effector killing cells, such as CD8+ T cell and natural killer (NK) cells, which regulate both adaptive and innate immunity.

Detailed analysis, characterization, and verification is critical to on-going success with any experiment. Learn more about workflow solutions for immuno-oncology research, from targeted genetic analysis through protein analysis.

Featured articles | New product releases | Resources and guides | News and views, Immunotherapies, which refocus an individual’s immune system to better fight disease, have shown promise in the treatment of cancer as well as other diseases.

Adoptive cell therapy (ACT) has emerged as an effective approach in immuno-oncology research. In recent years, personalized cancer immunotherapy in the form of chimeric antigen receptors (CARs) in T cells (CAR T cells) has effectively treated some forms of leukemia and lymphoma.

Reagents, assays, consumables, and software for use with the Ion GeneStudio S5 System., For use with all S5 or S5 XL sequencing workflows, Catalog # Product Size 969056 Acrometrix® Oncology Hotspot Control 3 x 25 µL Contact AMXSERVICE(Acrometrix-customs@lifetech.